Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy ...

BioNTech has initiated a Phase III clinical trial for its oncology candidate BNT324 in metastatic castration-resistant prostate cancer, aiming to compare the drug against current standard chemotherapy ...

This article summarizes metabolic reprogramming in prostate cancer (PCa). Early PCa relies more on glycolysis.

Drs Dean Ornish and Peter Carroll presented their research on the effects of an intensive lifestyle program on outcomes for patients with prostate cancer.

New research shows that vegetables and probiotics may help to stabilise or retard tumour growth in the prostate.

Basel, October 19, 2025 – Novartis today presents new Pluvicto™ (lutetium (177 Lu) vipivotide tetraxetan) data from the Phase III PSMAddition trial in a Presidential Symposium at the European Society ...

Prostate cancer (PCa) remains a significant global health challenge, with rising morbidity rates and poor prognosis associated with advanced stages ...

Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic body radiotherapy (SBRT) went more than twice as long without their disease ...

In a statement, NICE said the new guidance for Talzenna will make it an option for around 2,400 people in England and reduce ...

Thousands of men with prostate cancer will be offered a life-extending drug on the NHS within weeks. For the first time patients whose prostate cancer has not spread will be able to receive the drug ...